Overview

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2034-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \<18 years of age with somatostatin receptor (SSTR)-positive tumors.

Phase:

PHASE1

Details

Lead Sponsor:

ITM Solucin GmbH

Treatments:

177Lu-octreotide, DOTA(0)-Tyr(3)-
amino-acid, glucose, and electrolyte solution